Welcome to Vascular Adviser

The Vascular Protection Resource
For

What is ‘Vascular Protection’?

Vascular disease and its many manifestations, including coronary artery disease (CAD) and peripheral artery disease (PAD), have a major impact on the lives of millions of patients and those around them. Major advances in surgical and medical management strategies have helped healthcare professionals reduce its impact. However, despite these advances, the residual risk of major adverse cardiac events remains high. Research into innovative strategies to address this residual risk is ongoing. Whether it is through the use of different combinations of antithrombotic drugs, reducing lipid levels or other disease mediators, the area of Vascular Protection is exciting and continues to evolve.

Overview of vascular protection strategies for the prevention of atherothrombotic events in coronary 02:23 min
PP-XAR-ALL-0191-1

The COMPASS Trial: Rationale and Results

Find out how the risk of cardiovascular events was reduced in patients with CAD and PAD in the COMPASS trial

Approval Code: PP-XAR-ALL-0390-1

The COMPASS Trial: Rationale and Results 02:38 min
Since we launched VascularAdviser.com on August 26th 2017
People
Have died of a cardiovascular event*

*Calculation based on the proportion of the 17.7 million deaths due to cardiovascular disease in 1 year (or approximately 50,000 people per day).

  1. World health organization. Fact sheet No. 317. http://www.who.int/mediacentre/factsheets/fs317/en/ Accessed July 2017.
    G.MKT.GM.XA.08.2017.1727

1/3

True or False. Symptoms of atherosclerosis are evident in the early stages of plaque formation?

A compensatory remodelling of the arterial wall maintains proper blood flow despite the onset of plaque formation in the early stages of atherosclerosis.

References:

  1. Lilly LS. Pathophysiology of Heart Disease. A Collaborative Project of Medical Students and Faculty. 2011
2/3

What is NOT a clinical consequence of atherosclerosis?

The protrusion of an atherosclerotic plaque into the lumen of an arterial vessel can lead to stenosis, with a dramatic decrease in blood supply to tissues resulting in ischemia.

References:

  1. Lilly LS. Pathophysiology of Heart Disease. A Collaborative Project of Medical Students and Faculty. 2011
3/3

Which one of the following statements is false?

Thrombin is central to both pathways involved in thrombus formation via its roles in catalyzing the conversion of fibrinogen to fibrin and activating platelets. Fibrin formation and platelet aggregation form the final steps in forming a stable thrombus.

References:

  1. DeLoughery TG. Basics of coagulation. In: DeLoughery TG, ed. Hemostasis and Thrombosis. Third Edition. Springer 2015, Chapter 1, pp1-8.
  2. White H. Clin Applied Thromb Hemost 2014;20:516-523.

Here is your score

1/4

What are the two main pathways that lead to thrombus formation?

A “platelet” and a “thrombin” pathway, which leads to the aggregation of platelets and fibrin formation, respectively, intersect to drive thrombus formation.

References:

  1. Weitz JI. Thromb Haemost 2014;112:924-931
2/4

Which of the following statements is false?

Polyvascular disease is associated with a significantly increased risk of cardiovascular death and cardiovascular events. More than one study has shown that more than one vascular bed is affected in a number of patients with atherosclerotic disease.

References:

  1. Vlachopoulos C, Naka K. Chapter 202. Polyvascular disease: principles of diagnosis and management. In: Lanzer P (ed), PanVascular Medicine. 2015:4811-4835
  2. Aboyans V. Polyvascular disease: definition, epidemiology, and relevance. PanVascular Medicine. 2014;1-37.
3/4

In the REACH Registry, what percentage of patients with symptomatic atherothrombosis had symptomatic polyvascular disease?

The REACH Registry showed that 15.9% of patients with symptomatic atherothrombosis also had symptomatic polyvascular disease.

References:

  1. Bhatt DL, et al. JAMA 2006;295:180–189.
  2. Bhatt DL, Peterson ED, Harrington RA, et al. Prior polyvascular disease: risk factor for adverse ischaemia outcomes in acute coronary syndromes. Eur Heart J. 2009;30:1195-1202.
  3. Aboyans V. Polyvascular disease: definition, epidemiology, and relevance. PanVascular Medicine. 2014;1-37.
4/4

Globally, how many deaths did coronary heart disease and stroke (combined) cause in 2015?

Globally, coronary heart disease and stroke had the largest mortality rates, accounting for a combined 15 million deaths in 2015. These diseases have remained the leading causes of death globally over the last 15 years.

References:

  1. WHO 2017. Factsheet 210. The top 10 causes of death. http://www.who.int/mediacentre/factsheets/fs310/en. Accessed 21 June 2017

Here is your score

1/3

Which of the following statements is false?

There appears to be a trend for an increased number of cardiovascular deaths with advancing age. Using the latest available data from countries across Europe from the WHO mortality database, Townsend et al. showed that 683,364 individuals aged <65 years died prematurely due to cardiovascular disease compared with 1,407,040 individual aged <75 years. Globally, cardiovascular diseases were responsible for the largest proportion of non-communicable disease-related deaths in people aged below 60 years and in those aged below 70 years.

References:

  1. Townsend N, et al. Eur Heart J 2016;37:3232–45
2/3

Based on the Framingham Heart Study, to approximately what age would a 60-year-old patient with a history of myocardial infarction be expected to live?

In the Framingham heart Study, a 60-year-old patient with atherothrombosis and a history of myocardial infarction was only expected to live approximately 11 more years.

References:

  1. Bakhai A. Pharmacoeconomics 2004;22:11–8.
3/3

What is the expected cost of cardiovascular disease in the year 2030?

As of 2010, the global cost of cardiovascular disease was US $863 billion; this cost is expected to rise to US $1,044 billion by the year 2030.

References:

  1. World Heart Federation. http://www.championadvocates.org/en/champion-advocates-programme/the-costs-of-cvd/ .Accessed 23 June 2017

Here is your score

A patient’s perspective: Coronary and Peripheral Artery Diseases

A patient’s story of their experience with coronary and peripheral artery diseases, and how new therapeutic approaches helped their treatment and recovery.

G.MKT.GM.XA.08.2017.1696

A patient’s story: CAD and PAD 03:43 min

Vascular Frontiers

Find out more about Bayer's Vascular IIR Research Programme.

LEARN MORE

Clinical advances in anticoagulation management and Vascular Protection

Access the independent CME activities on Medscape!

ACCESS CME

Sign up to the Thrombosis Adviser Newsletter

Sign Up for News on Thrombosis Care, Vascular Protection and Future Updates from Bayer

Subscribe